Antibacterial activity of cefepime in vitro

Y. C. Liu, W. K. Huang, D. L. Cheng

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Cefepime is a new parenterally active fourth-generation cephalosporin which is undergoing in vitro and in vivo evaluations. Using the standard agar dilution method we compared the in vitro activity of this drug with other cephalosporins and ciprofloxacin against clinical isolates of Escherichia coli (98 strains), Klebsiella pneumoniae (99 strains), Acinetobacter spp. (24 strains), Pseudomonas aeruginosa (98 strains), Haemophilus influenzae (108 strains), Staphylococcus aureus (100 strains), Enterococcus spp. (45 strains), Streptococcus pneumoniae (10 strains), Streptococcus pyogenes (group A; 19 strains) and Streptococcus agalactiae (group B; 36 strains). Cefepime showed excellent activity against E. coli and K. pneumoniae, inhibiting 90% of these isolates at 0.12 mg/l. The in vitro activity of cefepime was superior to or comparable to the third-generation cephalosporins tested but was inferior to ciprofloxacin against Acinetobacter spp. and P. aeruginosa. Against H. influenzae, whether or not the strains produced β-lactamase, its activity was similar to comparable drugs. All 84 isolates of methicillin-susceptible S. aureus were inhibited by 8 mg/l of cefepime whereas, like other cephalosporins, it had little activity against methicillin-resistant S. aureus. Of the 45 enterococci isolates tested, 44.4% were inhibited by 8 mg/l of cefepime. Against streptococci, its activity was superior to any drug tested. This in vitro study indicates that cefepime has the potential to be a valuable agent for the treatment of community- and hospital-acquired cutaneous, respiratory and urinary tract infections.

Original languageEnglish
Pages (from-to)384-390
Number of pages7
JournalChemotherapy
Volume40
Issue number6
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Cephalosporins
Acinetobacter
Streptococcus agalactiae
Enterococcus
Haemophilus influenzae
Klebsiella pneumoniae
Ciprofloxacin
Pseudomonas aeruginosa
Staphylococcus aureus
Pharmaceutical Preparations
Escherichia coli
Methicillin
Streptococcus pyogenes
Community Hospital
Methicillin-Resistant Staphylococcus aureus
Streptococcus pneumoniae
Streptococcus
Urinary Tract Infections
Respiratory Tract Infections
Agar

Keywords

  • Antibiotics
  • Cephalosporins
  • Sensitivity

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Liu, Y. C., Huang, W. K., & Cheng, D. L. (1994). Antibacterial activity of cefepime in vitro. Chemotherapy, 40(6), 384-390.

Antibacterial activity of cefepime in vitro. / Liu, Y. C.; Huang, W. K.; Cheng, D. L.

In: Chemotherapy, Vol. 40, No. 6, 1994, p. 384-390.

Research output: Contribution to journalArticle

Liu, YC, Huang, WK & Cheng, DL 1994, 'Antibacterial activity of cefepime in vitro', Chemotherapy, vol. 40, no. 6, pp. 384-390.
Liu YC, Huang WK, Cheng DL. Antibacterial activity of cefepime in vitro. Chemotherapy. 1994;40(6):384-390.
Liu, Y. C. ; Huang, W. K. ; Cheng, D. L. / Antibacterial activity of cefepime in vitro. In: Chemotherapy. 1994 ; Vol. 40, No. 6. pp. 384-390.
@article{926992d986ea4845a3daf601b4fda1e5,
title = "Antibacterial activity of cefepime in vitro",
abstract = "Cefepime is a new parenterally active fourth-generation cephalosporin which is undergoing in vitro and in vivo evaluations. Using the standard agar dilution method we compared the in vitro activity of this drug with other cephalosporins and ciprofloxacin against clinical isolates of Escherichia coli (98 strains), Klebsiella pneumoniae (99 strains), Acinetobacter spp. (24 strains), Pseudomonas aeruginosa (98 strains), Haemophilus influenzae (108 strains), Staphylococcus aureus (100 strains), Enterococcus spp. (45 strains), Streptococcus pneumoniae (10 strains), Streptococcus pyogenes (group A; 19 strains) and Streptococcus agalactiae (group B; 36 strains). Cefepime showed excellent activity against E. coli and K. pneumoniae, inhibiting 90{\%} of these isolates at 0.12 mg/l. The in vitro activity of cefepime was superior to or comparable to the third-generation cephalosporins tested but was inferior to ciprofloxacin against Acinetobacter spp. and P. aeruginosa. Against H. influenzae, whether or not the strains produced β-lactamase, its activity was similar to comparable drugs. All 84 isolates of methicillin-susceptible S. aureus were inhibited by 8 mg/l of cefepime whereas, like other cephalosporins, it had little activity against methicillin-resistant S. aureus. Of the 45 enterococci isolates tested, 44.4{\%} were inhibited by 8 mg/l of cefepime. Against streptococci, its activity was superior to any drug tested. This in vitro study indicates that cefepime has the potential to be a valuable agent for the treatment of community- and hospital-acquired cutaneous, respiratory and urinary tract infections.",
keywords = "Antibiotics, Cephalosporins, Sensitivity",
author = "Liu, {Y. C.} and Huang, {W. K.} and Cheng, {D. L.}",
year = "1994",
language = "English",
volume = "40",
pages = "384--390",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Antibacterial activity of cefepime in vitro

AU - Liu, Y. C.

AU - Huang, W. K.

AU - Cheng, D. L.

PY - 1994

Y1 - 1994

N2 - Cefepime is a new parenterally active fourth-generation cephalosporin which is undergoing in vitro and in vivo evaluations. Using the standard agar dilution method we compared the in vitro activity of this drug with other cephalosporins and ciprofloxacin against clinical isolates of Escherichia coli (98 strains), Klebsiella pneumoniae (99 strains), Acinetobacter spp. (24 strains), Pseudomonas aeruginosa (98 strains), Haemophilus influenzae (108 strains), Staphylococcus aureus (100 strains), Enterococcus spp. (45 strains), Streptococcus pneumoniae (10 strains), Streptococcus pyogenes (group A; 19 strains) and Streptococcus agalactiae (group B; 36 strains). Cefepime showed excellent activity against E. coli and K. pneumoniae, inhibiting 90% of these isolates at 0.12 mg/l. The in vitro activity of cefepime was superior to or comparable to the third-generation cephalosporins tested but was inferior to ciprofloxacin against Acinetobacter spp. and P. aeruginosa. Against H. influenzae, whether or not the strains produced β-lactamase, its activity was similar to comparable drugs. All 84 isolates of methicillin-susceptible S. aureus were inhibited by 8 mg/l of cefepime whereas, like other cephalosporins, it had little activity against methicillin-resistant S. aureus. Of the 45 enterococci isolates tested, 44.4% were inhibited by 8 mg/l of cefepime. Against streptococci, its activity was superior to any drug tested. This in vitro study indicates that cefepime has the potential to be a valuable agent for the treatment of community- and hospital-acquired cutaneous, respiratory and urinary tract infections.

AB - Cefepime is a new parenterally active fourth-generation cephalosporin which is undergoing in vitro and in vivo evaluations. Using the standard agar dilution method we compared the in vitro activity of this drug with other cephalosporins and ciprofloxacin against clinical isolates of Escherichia coli (98 strains), Klebsiella pneumoniae (99 strains), Acinetobacter spp. (24 strains), Pseudomonas aeruginosa (98 strains), Haemophilus influenzae (108 strains), Staphylococcus aureus (100 strains), Enterococcus spp. (45 strains), Streptococcus pneumoniae (10 strains), Streptococcus pyogenes (group A; 19 strains) and Streptococcus agalactiae (group B; 36 strains). Cefepime showed excellent activity against E. coli and K. pneumoniae, inhibiting 90% of these isolates at 0.12 mg/l. The in vitro activity of cefepime was superior to or comparable to the third-generation cephalosporins tested but was inferior to ciprofloxacin against Acinetobacter spp. and P. aeruginosa. Against H. influenzae, whether or not the strains produced β-lactamase, its activity was similar to comparable drugs. All 84 isolates of methicillin-susceptible S. aureus were inhibited by 8 mg/l of cefepime whereas, like other cephalosporins, it had little activity against methicillin-resistant S. aureus. Of the 45 enterococci isolates tested, 44.4% were inhibited by 8 mg/l of cefepime. Against streptococci, its activity was superior to any drug tested. This in vitro study indicates that cefepime has the potential to be a valuable agent for the treatment of community- and hospital-acquired cutaneous, respiratory and urinary tract infections.

KW - Antibiotics

KW - Cephalosporins

KW - Sensitivity

UR - http://www.scopus.com/inward/record.url?scp=0028080020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028080020&partnerID=8YFLogxK

M3 - Article

C2 - 7842821

AN - SCOPUS:0028080020

VL - 40

SP - 384

EP - 390

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 6

ER -